March 3, 2026Journal of Clinical Oncology10 citations
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2
Olaparib shows significant activity in metastatic breast cancer patients with germline PALB2 mutations and somatic BRCA mutations.
The study identifies a greater population of breast cancer patients likely to benefit from PARP inhibitors, specifically beyond BRCA1 and BRCA2 carriers.
Patients with PALB2 or BRCA mutations exhibit enhanced responses, implying that treatment can be expanded for those typically excluded.
This research supports developing targeted therapies aimed at broader genetic profiles in cancer management.
Abstract
Olaparib is active in pts with MBC with gPALB2m and sBRCAm, significantly expanding the population of pts with breast cancer likely to benefit from PARP inhibitors beyond gBRCA1/2m carriers.